New data confirms cancer-fighting potential
Open PDF
| Stock | Noxopharm Ltd (NOX.ASX) |
|---|---|
| Release Time | 26 May 2026, 8:21 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Noxopharm Announces New Cancer-Fighting Data
Key Points
- Novel immune activation approach shown in ex vivo and in vivo experiments
- Builds on breakthrough immune system discovery
- Market projected to reach US$185 billion by 2035
Full Summary
Noxopharm Ltd. announced new data showing how its Sofra technology platform will be leveraged to fight cancer. The field of immuno-oncology, which involves harnessing the body's own immune system to destroy cancer cells, has reshaped cancer treatment over recent years and helped millions of patients. The market is projected to grow from US$35 billion in 2025 to US$185 billion by 2035. Noxopharm is currently advancing a drug development program aimed at harnessing the power of TLR8 against cancer. The company has developed oligonucleotides capable of greatly amplifying the activity of TLR8 compared to current best-in-class drugs in clinical development.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In